Vaccine

CytoDyn to Host R&D Update on Wednesday, December 7, 2022

VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…

2 years ago

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,…

2 years ago

IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022

LAWRENCEVILLE, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr.…

2 years ago

Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer

Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries…

2 years ago

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron…

2 years ago

Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

BLA Submission Ongoing with U.S. Food and Drug AdministrationSAN CARLOS, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.…

2 years ago

IMUNON Announces Strategic Investment in Transomic Technologies

Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive…

2 years ago

Gritstone to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to…

2 years ago

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies…

2 years ago

Velocity Clinical Research expands to UK

From right to left: Shivagami Muthiah, Business Director of Egin Research; Dr. Ahmed Elshashai, Chief Investigator at Egin Research; Dominic…

2 years ago